Atp-sensitive potassium channel modulators and cardiac arrhythmias: An update

Current Pharmaceutical Design

Volumn 21, Issue 8, 2015, Pages 1091-1102

  Muntean, Danina M ^a   Kiss, Loránd ^b   Jost, Norbert ^a,c   Baczkó, István ^a,c  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Cardiac arrhythmias; Pharmacological modulators; Sarcolemmal and Mitochondrial ATP Sensitive Potassium Channels

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ANTIARRHYTHMIC AGENT; MITOCHONDRIAL ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; SARCOLEMMAL ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ARRHYTHMOGENESIS; ARTICLE; DRUG MECHANISM; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; METABOLIC STRESS; MITOCHONDRIAL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ARRHYTHMIAS, CARDIAC; DRUG EFFECTS; HEART; PATHOPHYSIOLOGY; PHYSIOLOGY; SARCOLEMMA; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; HEART; HUMANS; KATP CHANNELS; SARCOLEMMA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84925847808     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141029102800     Document Type: Article

References (171)

1. Noma A. ATP-regulated K+ channels in cardiac muscle. Nature, 1983; 305: 147-8.
2. Inoue I, Nagase H, Kishi K, Higuti T. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature, 1991; 352: 244-7.
3. Terzic A, Jahangir A, Kurachi Y. Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channelopening drugs. Am J Physiol, 1995; 269: C525-45.
4. Nichols CG. KATP channels as molecular sensors of cellular metabolism. Nature, 2006; 440: 470-6.
5. Deutsch N, Klitzner TS, Lamp ST, Weiss JN. Activation of cardiac ATP-sensitive K+ current during hypoxia: correlation with tissue ATP levels. Am J Physiol, 1991; 261: H671-6.
6. Nichols CG, Ripoll C, Lederer WJ. ATP-sensitive potassium channel modulation of the guinea pig ventricular action potential and contraction. Circ Res, 1991; 68: 280-7.
7. Elliott AC, Smith GL, Allen DG. Simultaneous measurements of action potential duration and intracellular ATP in isolated ferret hearts exposed to cyanide. Circ Res, 1989; 64: 583-91.
8. Faivre JF, Findlay I. Action potential duration and activation of ATP-sensitive potassium current in isolated guinea-pig ventricular myocytes. Biochim Biophys Acta, 1990; 1029: 167-72.
9. Flagg TP, Enkvetchakul D, Koster JC, Nichols CG. Muscle KATP channels: recent insights to energy sensing and myoprotection. Physiol Rev, 2010; 90: 799-829.
10. Suzuki M, Sasaki N, Miki T, Sakamoto N, Ohmoto-Sekine Y, Tamagawa M, Seino S, Marban E, Nakaya H. Role of sarcolemmal K(ATP) channels in cardioprotection against ischemia/reperfusion injury in mice. J Clin Invest, 2002; 109: 509-16.
11. Remme CA, Wilde AA. KATP channel openers, myocardial ischemia, and arrhythmias--should the electrophysiologist worry? Cardiovasc Drugs Ther, 2000; 14: 17-22.
12. O'Rourke B. Mitochondrial ion channels. Annu Rev Physiol, 2007; 69: 19-49.
13. Gross GJ. The role of mitochondrial KATP channels in cardioprotection. Basic Res Cardiol, 2000; 95: 280-4.
14. Garlid KD, Dos Santos P, Xie ZJ, Costa AD, Paucek P. Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K(+) channel in cardiac function and cardioprotection. Biochim Biophys Acta, 2003; 1606: 1-21.
15. Oldenburg O, Cohen MV, Downey JM. Mitochondrial K(ATP) channels in preconditioning. J Mol Cell Cardiol, 2003; 35: 569-75.
16. Shi W, Vinten-Johansen J. Endogenous cardioprotection by ischaemic postconditioning and remote conditioning. Cardiovasc Res, 2012; 94: 206-16.
17. Garlid KD, Halestrap AP. The mitochondrial K(ATP) channel--fact or fiction? J Mol Cell Cardiol, 2012; 52: 578-83.
18. Lefer DJ, Nichols CG, Coetzee WA. Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury. Trends Cardiovasc Med, 2009; 19: 61-7.
19. Brown DA, O'Rourke B. Cardiac mitochondria and arrhythmias. Cardiovasc Res, 2010; 88: 241-9.
20. Kane GC, Liu XK, Yamada S, Olson TM, Terzic A. Cardiac KATP channels in health and disease. J Mol Cell Cardiol, 2005; 38: 937-43.
21. Zhang H, Flagg TP, Nichols CG. Cardiac sarcolemmal K(ATP) channels: Latest twists in a questing tale! J Mol Cell Cardiol, 2010; 48: 71-5.
22. Inagaki N, Tsuura Y, Namba N, Masuda K, Gonoi T, Horie M, Seino Y, Mizuta M, Seino S. Cloning and functional characterization of a novel ATP-sensitive potassium channel ubiquitously expressed in rat tissues, including pancreatic islets, pituitary, skeletal muscle, and heart. J Biol Chem, 1995; 270: 5691-4.
23. Chutkow WA, Simon MC, Le Beau MM, Burant CF. Cloning, tissue expression, and chromosomal localization of SUR2, the putative drug-binding subunit of cardiac, skeletal muscle, and vascular KATP channels. Diabetes, 1996; 45: 1439-45.
24. Seino S. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies. Annu Rev Physiol, 1999; 61: 337-62.
25. Seino S, Miki T. Gene targeting approach to clarification of ion channel function: studies of Kir6.x null mice. J Physiol, 2004; 554: 295-300.
26. Kefaloyianni E, Bao L, Rindler MJ, Hong M, Patel T, Taskin E, Coetzee WA. Measuring and evaluating the role of ATP-sensitive K+ channels in cardiac muscle. J Mol Cell Cardiol, 2012; 52: 596-607.
27. Kefaloyianni E, Lyssand JS, Moreno C, Delaroche D, Hong M, Fenyo D, Mobbs CV, Neubert TA, Coetzee WA. Comparative proteomic analysis of the ATP-sensitive K+ channel complex in different tissue types. Proteomics, 2013; 13: 368-78.
28. Flagg TP, Nichols CG. "Cardiac KATP": a family of ion channels. Circ Arrhythm Electrophysiol, 2011; 4: 796-8.
29. Flagg TP, Kurata HT, Masia R, Caputa G, Magnuson MA, Lefer DJ, Coetzee WA, Nichols CG. Differential structure of atrial and ventricular KATP: atrial KATP channels require SUR1. Circ Res, 2008; 103: 1458-65.
30. Glukhov AV, Flagg TP, Fedorov VV, Efimov IR, Nichols CG. Differential K(ATP) channel pharmacology in intact mouse heart. J Mol Cell Cardiol, 2010; 48: 152-60.
31. Bao L, Kefaloyianni E, Lader J, Hong M, Morley G, Fishman GI, Sobie EA, Coetzee WA. Unique properties of the ATP-sensitive K(+) channel in the mouse ventricular cardiac conduction system. Circ Arrhythm Electrophysiol, 2011; 4: 926-35.
32. Poitry S, van Bever L, Coppex F, Roatti A, Baertschi AJ. Differential sensitivity of atrial and ventricular K(ATP) channels to metabolic inhibition. Cardiovasc Res, 2003; 57: 468-76.
33. Zhang HX, Silva JR, Lin YW, Verbsky JW, Lee US, Kanter EM, Yamada KA, Schuessler RB, Nichols CG. Heterogeneity and function of K(ATP) channels in canine hearts. Heart Rhythm, 2013; 10: 1576-83.
34. Fedorov VV, Glukhov AV, Ambrosi CM, Kostecki G, Chang R, Janks D, Schuessler RB, Moazami N, Nichols CG, Efimov IR. Effects of KATP channel openers diazoxide and pinacidil in coronary-perfused atria and ventricles from failing and non-failing human hearts. J Mol Cell Cardiol, 2011; 51: 215-25.
35. Carrasco AJ, Dzeja PP, Alekseev AE, Pucar D, Zingman LV, Abraham MR, Hodgson D, Bienengraeber M, Puceat M, Janssen E, Wieringa B, Terzic A. Adenylate kinase phosphotransfer communicates cellular energetic signals to ATP-sensitive potassium channels. Proc Natl Acad Sci U S A, 2001; 98: 7623-8.
36. Crawford RM, Ranki HJ, Botting CH, Budas GR, Jovanovic A. Creatine kinase is physically associated with the cardiac ATPsensitive K+ channel in vivo. FASEB J, 2002; 16: 102-4.
37. Abraham MR, Selivanov VA, Hodgson DM, Pucar D, Zingman LV, Wieringa B, Dzeja PP, Alekseev AE, Terzic A. Coupling of cell energetics with membrane metabolic sensing. Integrative signaling through creatine kinase phosphotransfer disrupted by MCK gene knock-out. J Biol Chem, 2002; 277: 24427-34.
38. Selivanov VA, Alekseev AE, Hodgson DM, Dzeja PP, Terzic A. Nucleotide-gated KATP channels integrated with creatine and adenylate kinases: amplification, tuning and sensing of energetic signals in the compartmentalized cellular environment. Mol Cell Biochem, 2004; 256-257: 243-56.
39. Alekseev AE, Hodgson DM, Karger AB, Park S, Zingman LV, Terzic A. ATP-sensitive K+ channel channel/enzyme multimer: metabolic gating in the heart. J Mol Cell Cardiol, 2005; 38: 895-905.
40. Dhar-Chowdhury P, Harrell MD, Han SY, Jankowska D, Parachuru L, Morrissey A, Srivastava S, Liu W, Malester B, Yoshida H, Coetzee WA. The glycolytic enzymes, glyceraldehyde-3-phosphate dehydrogenase, triose-phosphate isomerase, and pyruvate kinase are components of the K(ATP) channel macromolecular complex and regulate its function. J Biol Chem, 2005; 280: 38464-70.
41. Hong M, Kefaloyianni E, Bao L, Malester B, Delaroche D, Neubert TA, Coetzee WA. Cardiac ATP-sensitive K+ channel associates with the glycolytic enzyme complex. FASEB J, 2011; 25: 2456-67.
42. Crawford RM, Budas GR, Jovanovic S, Ranki HJ, Wilson TJ, Davies AM, Jovanovic A. M-LDH serves as a sarcolemmal K(ATP) channel subunit essential for cell protection against ischemia. EMBO J, 2002; 21: 3936-48.
43. Jovanovic S, Du Q, Sukhodub A, Jovanovic A. M-LDH physically associated with sarcolemmal K ATP channels mediates cytoprotection in heart embryonic H9C2 cells. Int J Biochem Cell Biol, 2009; 41: 2295-301.
44. Beguin P, Nagashima K, Nishimura M, Gonoi T, Seino S. PKAmediated phosphorylation of the human K(ATP) channel: separate roles of Kir6.2 and SUR1 subunit phosphorylation. EMBO J, 1999; 18: 4722-32.
45. Light PE, Bladen C, Winkfein RJ, Walsh MP, French RJ. Molecular basis of protein kinase C-induced activation of ATPsensitive potassium channels. Proc Natl Acad Sci U S A, 2000; 97: 9058-63.
46. Yoshida H, Bao L, Kefaloyianni E, Taskin E, Okorie U, Hong M, Dhar-Chowdhury P, Kaneko M, Coetzee WA. AMP-activated protein kinase connects cellular energy metabolism to KATP channel function. J Mol Cell Cardiol, 2012; 52: 410-8.
47. Weiss JN, Lamp ST. Glycolysis preferentially inhibits ATPsensitive K+ channels in isolated guinea pig cardiac myocytes. Science, 1987; 238: 67-9.
48. O'Rourke B, Ramza BM, Marban E. Oscillations of membrane current and excitability driven by metabolic oscillations in heart cells. Science, 1994; 265: 962-6.
49. Morita N, Lee JH, Bapat A, Fishbein MC, Mandel WJ, Chen PS, Weiss JN, Karagueuzian HS. Glycolytic inhibition causes spontaneous ventricular fibrillation in aged hearts. Am J Physiol Heart Circ Physiol, 2011; 301: H180-91.
50. Shibayama J, Taylor TG, Venable PW, Rhodes NL, Gil RB, Warren M, Wende AR, Abel ED, Cox J, Spitzer KW, Zaitsev AV. Metabolic determinants of electrical failure in ex-vivo canine model of cardiac arrest: evidence for the protective role of inorganic pyrophosphate. PLoS One, 2013; 8: e57821.
51. Schulze D, Rapedius M, Krauter T, Baukrowitz T. Long-chain acyl-CoA esters and phosphatidylinositol phosphates modulate ATP inhibition of KATP channels by the same mechanism. J Physiol, 2003; 552: 357-67.
52. Schulze D, Krauter T, Fritzenschaft H, Soom M, Baukrowitz T. Phosphatidylinositol 4,5-bisphosphate (PIP2) modulation of ATP and pH sensitivity in Kir channels. A tale of an active and a silent PIP2 site in the N terminus. J Biol Chem, 2003; 278: 10500-5.
53. van der Vusse GJ, van Bilsen M. Free Fatty acids and postischemic myocardial function. Semin Cardiothorac Vasc Anesth, 2006; 10: 231-5.
54. Burley DS, Cox CD, Zhang J, Wann KT, Baxter GF. Natriuretic peptides modulate ATP-sensitive K(+) channels in rat ventricular cardiomyocytes. Basic Res Cardiol, 2014; 109: 402.
55. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation, 2009; 120: 1768-74.
56. Patton KK, Heckbert SR, Alonso A, Bahrami H, Lima JA, Burke G, Kronmal RA. N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. Heart, 2013; 99: 1832-6.
57. Wilde AA, Escande D, Schumacher CA, Thuringer D, Mestre M, Fiolet JW, Janse MJ. Potassium accumulation in the globally ischemic mammalian heart. A role for the ATP-sensitive potassium channel. Circ Res, 1990; 67: 835-43.
58. Wilde AA. Role of ATP-sensitive K+ channel current in ischemic arrhythmias. Cardiovasc Drugs Ther, 1993; 7 Suppl 3: 521-6.
59. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev, 1989; 69: 1049-169.
60. Billman GE. The cardiac sarcolemmal ATP-sensitive potassium channel as a novel target for anti-arrhythmic therapy. Pharmacol Ther, 2008; 120: 54-70.
61. Baczko I, Husti Z, Lang V, Lepran I, Light PE. Sarcolemmal KATP channel modulators and cardiac arrhythmias. Curr Med Chem, 2011; 18: 3640-61.
62. Baczko I, Giles WR, Light PE. Pharmacological activation of plasma-membrane KATP channels reduces reoxygenation-induced Ca(2+) overload in cardiac myocytes via modulation of the diastolic membrane potential. Br J Pharmacol, 2004; 141: 1059-67.
63. Baczko I, Jones L, McGuigan CF, Manning Fox JE, Gandhi M, Giles WR, Clanachan AS, Light PE. Plasma membrane KATP channel-mediated cardioprotection involves posthypoxic reductions in calcium overload and contractile dysfunction: mechanistic insights into cardioplegia. FASEB J, 2005; 19: 980-2.
64. Hong M, Bao L, Kefaloyianni E, Agullo-Pascual E, Chkourko H, Foster M, Taskin E, Zhandre M, Reid DA, Rothenberg E, Delmar M, Coetzee WA. Heterogeneity of ATP-sensitive K+ channels in cardiac myocytes: enrichment at the intercalated disk. J Biol Chem, 2012; 287: 41258-67.
65. MacDonald RL, Hsu D, Mann JE, Jr., Sperelakis N. An analysis of the problem of K-+ accumulation in the intercalated disk clefts of cardiac muscle. J Theor Biol, 1975; 51: 455-73.
66. Sperelakis N. The possibility of propagation between myocardial cells not connected by low-resistance pathways. Adv Exp Med Biol, 1983; 161: 1-23.
67. Flagg TP, Patton B, Masia R, Mansfield C, Lopatin AN, Yamada KA, Nichols CG. Arrhythmia susceptibility and premature death in transgenic mice overexpressing both SUR1 and Kir6.2[DeltaN30,K185Q] in the heart. Am J Physiol Heart Circ Physiol, 2007; 293: H836-45.
68. Zingman LV, Hodgson DM, Bast PH, Kane GC, Perez-Terzic C, Gumina RJ, Pucar D, Bienengraeber M, Dzeja PP, Miki T, Seino S, Alekseev AE, Terzic A. Kir6.2 is required for adaptation to stress. Proc Natl Acad Sci U S A, 2002; 99: 13278-83.
69. Gumina RJ, O'Cochlain DF, Kurtz CE, Bast P, Pucar D, Mishra P, Miki T, Seino S, Macura S, Terzic A. KATP channel knockout worsens myocardial calcium stress load in vivo and impairs recovery in stunned heart. Am J Physiol Heart Circ Physiol, 2007; 292: H1706-13.
70. Varro A, Baczko I. Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. Br J Pharmacol, 2011; 164: 14-36.
71. Liu XK, Yamada S, Kane GC, Alekseev AE, Hodgson DM, O'Cochlain F, Jahangir A, Miki T, Seino S, Terzic A. Genetic disruption of Kir6.2, the pore-forming subunit of ATP-sensitive K+ channel, predisposes to catecholamine-induced ventricular dysrhythmia. Diabetes, 2004; 53 Suppl 3: S165-8.
72. Olson TM, Alekseev AE, Moreau C, Liu XK, Zingman LV, Miki T, Seino S, Asirvatham SJ, Jahangir A, Terzic A. KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat Clin Pract Cardiovasc Med, 2007; 4: 110-6.
73. Gaborit N, Varro A, Le Bouter S, Szuts V, Escande D, Nattel S, Demolombe S. Gender-related differences in ion-channel and transporter subunit expression in non-diseased human hearts. J Mol Cell Cardiol, 2010; 49: 639-46.
74. Xie LH, John SA, Ribalet B, Weiss JN. Activation of inwardly rectifying potassium (Kir) channels by phosphatidylinosital-4,5-bisphosphate (PIP2): interaction with other regulatory ligands. Prog Biophys Mol Biol, 2007; 94: 320-35.
75. Cameron JS, Kimura S, Jackson-Burns DA, Smith DB, Bassett AL. ATP-sensitive K+ channels are altered in hypertrophied ventricular myocytes. Am J Physiol, 1988; 255: H1254-8.
76. Brundel BJ, Van Gelder IC, Henning RH, Tuinenburg AE, Wietses M, Grandjean JG, Wilde AA, Van Gilst WH, Crijns HJ. Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. J Am Coll Cardiol, 2001; 37: 926-32.
77. Balana B, Dobrev D, Wettwer E, Christ T, Knaut M, Ravens U. Decreased ATP-sensitive K(+) current density during chronic human atrial fibrillation. J Mol Cell Cardiol, 2003; 35: 1399-405.
78. Nattel S. Remodeling of cardiac inward-rectifier currents: an oftenoverlooked contributor to arrhythmogenic states. J Mol Cell Cardiol, 2003; 35: 1395-8.
79. Hodgson DM, Zingman LV, Kane GC, Perez-Terzic C, Bienengraeber M, Ozcan C, Gumina RJ, Pucar D, O'Coclain F, Mann DL, Alekseev AE, Terzic A. Cellular remodeling in heart failure disrupts K(ATP) channel-dependent stress tolerance. EMBO J, 2003; 22: 1732-42.
80. Medeiros-Domingo A, Tan BH, Crotti L, Tester DJ, Eckhardt L, Cuoretti A, Kroboth SL, Song C, Zhou Q, Kopp D, Schwartz PJ, Makielski JC, Ackerman MJ. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm, 2010; 7: 1466-71.
81. Barajas-Martinez H, Hu D, Ferrer T, Onetti CG, Wu Y, Burashnikov E, Boyle M, Surman T, Urrutia J, Veltmann C, Schimpf R, Borggrefe M, Wolpert C, Ibrahim BB, Sanchez-Chapula JA, Winters S, Haissaguerre M, Antzelevitch C. Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm, 2012; 9: 548-55.
82. Vereckei A, Gogelein H, Wirth KJ, Zipes DP. Effect of the cardioselective, sarcolemmal K(ATP) channel blocker HMR 1098 on atrial electrical remodeling during pacing-induced atrial fibrillation in dogs. Cardiovasc Drugs Ther, 2004; 18: 23-30.
83. Farid TA, Nair K, Masse S, Azam MA, Maguy A, Lai PF, Umapathy K, Dorian P, Chauhan V, Varro A, Al-Hesayen A, Waxman M, Nattel S, Nanthakumar K. Role of KATP channels in the maintenance of ventricular fibrillation in cardiomyopathic human hearts. Circ Res, 2011; 109: 1309-18.
84. Fancher IS, Dick GM, Hollander JM. Diabetes mellitus reduces the function and expression of ATP-dependent K(+) channels in cardiac mitochondria. Life Sci, 2013; 92: 664-8.
85. Levitan I. Cholesterol and Kir channels. IUBMB Life, 2009; 61: 781-90.
86. Mathew V, Lerman A. Altered effects of potassium channel modulation in the coronary circulation in experimental hypercholesterolemia. Atherosclerosis, 2001; 154: 329-35.
87. Genda S, Miura T, Miki T, Ichikawa Y, Shimamoto K. K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol, 2002; 40: 1339-46.
88. Csonka C, Kupai K, Bencsik P, Gorbe A, Paloczi J, Zvara A, Puskas LG, Csont T, Ferdinandy P. Cholesterol-enriched diet inhibits cardioprotection by ATP-sensitive K+ channel activators cromakalim and diazoxide. Am J Physiol Heart Circ Physiol, 2014; 306: H405-13.
89. Yu L, Jin X, Cui N, Wu Y, Shi Z, Zhu D, Jiang C. Rosiglitazone selectively inhibits K(ATP) channels by acting on the K(IR) 6 subunit. Br J Pharmacol, 2012; 167: 26-36.
90. Sarraf M, Lu L, Ye S, Reiter MJ, Greyson CR, Schwartz GG. Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs. Cardiovasc Drugs Ther, 2012; 26: 195-204.
91. Kistamas K, Szentandrassy N, Hegyi B, Ruzsnavszky F, Vaczi K, Barandi L, Horvath B, Szebeni A, Magyar J, Banyasz T, Kecskemeti V, Nanasi PP. Effects of pioglitazone on cardiac ion currents and action potential morphology in canine ventricular myocytes. Eur J Pharmacol, 2013; 710: 10-9.
92. Lepran I, Baczko I, Varro A, Papp JG. ATP-sensitive potassium channel modulators: both pinacidil and glibenclamide produce antiarrhythmic activity during acute myocardial infarction in conscious rats. J Pharmacol Exp Ther, 1996; 277: 1215-20.
93. Baczko I, Lepran I, Papp JG. KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats. Eur J Pharmacol, 1997; 324: 77-83.
94. Vajda S, Baczko I, Lepran I. Selective cardiac plasma-membrane K(ATP) channel inhibition is defibrillatory and improves survival during acute myocardial ischemia and reperfusion. Eur J Pharmacol, 2007; 577: 115-23.
95. Rees SA, Curtis MJ. Pharmacological analysis in rat of the role of the ATP-sensitive potassium channel as a potential target for antifibrillatory intervention in acute myocardial ischaemia. J Cardiovasc Pharmacol, 1995; 26: 280-8.
96. Smallwood JK, Ertel PJ, Steinberg MI. Modification by glibenclamide of the electrophysiological consequences of myocardial ischaemia in dogs and rabbits. Naunyn Schmiedebergs Arch Pharmacol, 1990; 342: 214-20.
97. del Valle HF, Lascano EC, Negroni JA, Crottogini AJ. Glibenclamide effects on reperfusion-induced malignant arrhythmias and left ventricular mechanical recovery from stunning in conscious sheep. Cardiovasc Res, 2001; 50: 474-85.
98. Wolleben CD, Sanguinetti MC, Siegl PK. Influence of ATPsensitive potassium channel modulators on ischemia-induced fibrillation in isolated rat hearts. J Mol Cell Cardiol, 1989; 21: 783-8.
99. Pogatsa G, Koltai MZ, Balkanyi I, Devai I, Kiss V, Koszeghy A. The effect of various hypoglycaemic sulphonylureas on the cardiotoxicity of glycosides and arrhythmogenic activity due to myocardial ischaemia. Acta Physiol Hung, 1988; 71: 243-50.
100. Barrett TD, Walker MJ. Glibenclamide does not prevent action potential shortening induced by ischemia in anesthetized rabbits but reduces ischemia-induced arrhythmias. J Mol Cell Cardiol, 1998; 30: 999-1008.
101. Dhein S, Pejman P, Krusemann K. Effects of the I(K.ATP) blockers glibenclamide and HMR1883 on cardiac electrophysiology during ischemia and reperfusion. Eur J Pharmacol, 2000; 398: 273-84.
102. Zhang HL, Li YS, Fu SX, Yang XP. Effects of glibenclamide and tolbutamide on ischemia-and ouabain-induced arrhythmias and membrane potentials of ventricular myocardium from rat and guinea pig. Zhongguo Yao Li Xue Bao, 1991; 12: 398-402.
103. Bril A, Laville MP, Gout B. Effects of glibenclamide on ventricular arrhythmias and cardiac function in ischaemia and reperfusion in isolated rat heart. Cardiovasc Res, 1992; 26: 1069-76.
104. Tosaki A, Engelman DT, Engelman RM, Das DK. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts. J Pharmacol Exp Ther, 1995; 275: 1115-23.
105. Kantor PF, Coetzee WA, Carmeliet EE, Dennis SC, Opie LH. Reduction of ischemic K+ loss and arrhythmias in rat hearts. Effect of glibenclamide, a sulfonylurea. Circ Res, 1990; 66: 478-85.
106. El-Reyani NE, Bozdogan O, Baczko I, Lepran I, Papp JG. Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats. Eur J Pharmacol, 1999; 365: 187-92.
107. Gwilt M, Henderson CG, Orme J, Rourke JD. Effects of drugs on ventricular fibrillation and ischaemic K+ loss in a model of ischaemia in perfused guinea-pig hearts in vitro. Eur J Pharmacol, 1992; 220: 231-6.
108. Billman GE, Englert HC, Scholkens BA. HMR 1883, a novel cardioselective inhibitor of the ATP-sensitive potassium channel. Part II: effects on susceptibility to ventricular fibrillation induced by myocardial ischemia in conscious dogs. J Pharmacol Exp Ther, 1998; 286: 1465-73.
109. Pasnani JS, Ferrier GR. Differential effects of glyburide on premature beats and ventricular tachycardia in an isolated tissue model of ischemia and reperfusion. J Pharmacol Exp Ther, 1992; 262: 1076-84.
110. Billman GE, Avendano CE, Halliwill JR, Burroughs JM. The effects of the ATP-dependent potassium channel antagonist, glyburide, on coronary blood flow and susceptibility to ventricular fibrillation in unanesthetized dogs. J Cardiovasc Pharmacol, 1993; 21: 197-204.
111. Geisen K, Vegh A, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res, 1996; 28: 496-507.
112. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 1998; 352: 837-53.
113. Nagendran J, Oudit GY, Bakal JA, Light PE, Dyck JR, McAlister FA. Are users of sulphonylureas at the time of an acute coronary syndrome at risk of poorer outcomes? Diabetes Obes Metab, 2013; 15: 1022-8.
114. Wirth KJ, Rosenstein B, Uhde J, Englert HC, Busch AE, Scholkens BA. ATP-sensitive potassium channel blocker HMR 1883 reduces mortality and ischemia-associated electrocardiographic changes in pigs with coronary occlusion. J Pharmacol Exp Ther, 1999; 291: 474-81.
115. Wirth KJ, Klaus E, Englert HG, Scholkens BA, Linz W. HMR 1883, a cardioselective K(ATP) channel blocker, inhibits ischaemia-and reperfusion-induced ventricular fibrillation in rats. Naunyn Schmiedebergs Arch Pharmacol, 1999; 360: 295-300.
116. Zhu BM, Miyamoto S, Nagasawa Y, Wajima T, Hashimoto K. Effect of the sarcolemmal K(ATP) channel blocker HMR1098 on arrhythmias induced by programmed electrical stimulation in canine old myocardial infarction model: comparison with glibenclamide. J Pharmacol Sci, 2003; 93: 106-13.
117. Fischbach PS, White A, Barrett TD, Lucchesi BR. Risk of ventricular proarrhythmia with selective opening of the myocardial sarcolemmal versus mitochondrial ATP-gated potassium channel. J Pharmacol Exp Ther, 2004; 309: 554-9.
118. Gok S, Vural K, Sekuri C, Onur R, Tezcan A, Izanli A. Effects of the blockade of cardiac sarcolemmal ATP-sensitive potassium channels on arrhythmias and coronary flow in ischemia-reperfusion model in isolated rat hearts. Vascul Pharmacol, 2006; 44: 197-205.
119. Billman GE, Houle MS, Englert HC, Gogelein H. Effects of a novel cardioselective ATP-sensitive potassium channel antagonist, 1-[[5-[2-(5-chloro-o-anisamido)ethyl]-betamethoxyethoxyphenyl] sulfonyl]-3-methyl thiourea, sodium salt (HMR 1402), on susceptibility to ventricular fibrillation induced by myocardial ischemia: in vitro and in vivo studies. J Pharmacol Exp Ther, 2004; 309: 182-92.
120. Zhang HX, Akrouh A, Kurata HT, Remedi MS, Lawton JS, Nichols CG. HMR 1098 is not an SUR isotype specific inhibitor of heterologous or sarcolemmal K ATP channels. J Mol Cell Cardiol, 2011; 50: 552-60.
121. Paucek P, Mironova G, Mahdi F, Beavis AD, Woldegiorgis G, Garlid KD. Reconstitution and partial purification of the glibenclamide-sensitive, ATP-dependent K+ channel from rat liver and beef heart mitochondria. J Biol Chem, 1992; 267: 26062-9.
122. Paucek P, Yarov-Yarovoy V, Sun X, Garlid KD. Inhibition of the mitochondrial KATP channel by long-chain acyl-CoA esters and activation by guanine nucleotides. J Biol Chem, 1996; 271: 32084-8.
123. Facundo HT, Fornazari M, Kowaltowski AJ. Tissue protection mediated by mitochondrial K+ channels. Biochim Biophys Acta, 2006; 1762: 202-12.
124. Liu Y, Sato T, Seharaseyon J, Szewczyk A, O'Rourke B, Marban E. Mitochondrial ATP-dependent potassium channels. Viable candidate effectors of ischemic preconditioning. Ann N Y Acad Sci, 1999; 874: 27-37.
125. Oldenburg O, Cohen MV, Yellon DM, Downey JM. Mitochondrial K(ATP) channels: role in cardioprotection. Cardiovasc Res, 2002; 55: 429-37.
126. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev, 2008; 88: 581-609.
127. Mykytenko J, Reeves JG, Kin H, Wang NP, Zatta AJ, Jiang R, Guyton RA, Vinten-Johansen J, Zhao ZQ. Persistent beneficial effect of postconditioning against infarct size: role of mitochondrial K(ATP) channels during reperfusion. Basic Res Cardiol, 2008; 103: 472-84.
128. Dos Santos P, Kowaltowski AJ, Laclau MN, Seetharaman S, Paucek P, Boudina S, Thambo JB, Tariosse L, Garlid KD. Mechanisms by which opening the mitochondrial ATP-sensitive K(+) channel protects the ischemic heart. Am J Physiol Heart Circ Physiol, 2002; 283: H284-95.
129. Carreira RS, Facundo HT, Kowaltowski AJ. Mitochondrial K+ transport and cardiac protection during ischemia/reperfusion. Braz J Med Biol Res, 2005; 38: 345-52.
130. Carreira RS, Lee P, Gottlieb RA. Mitochondrial therapeutics for cardioprotection. Curr Pharm Des, 2011; 17: 2017-35.
131. Ardehali H, Chen Z, Ko Y, Mejia-Alvarez R, Marban E. Multiprotein complex containing succinate dehydrogenase confers mitochondrial ATP-sensitive K+ channel activity. Proc Natl Acad Sci U S A, 2004; 101: 11880-5.
132. Jaburek M, Costa AD, Burton JR, Costa CL, Garlid KD. Mitochondrial PKC epsilon and mitochondrial ATP-sensitive K+ channel copurify and coreconstitute to form a functioning signaling module in proteoliposomes. Circ Res, 2006; 99: 878-83.
133. Facundo HT, de Paula JG, Kowaltowski AJ. Mitochondrial ATPsensitive K+ channels are redox-sensitive pathways that control reactive oxygen species production. Free Radic Biol Med, 2007; 42: 1039-48.
134. Foster DB, Rucker JJ, Marban E. Is Kir6.1 a subunit of mitoK(ATP)? Biochem Biophys Res Commun, 2008; 366: 649-56.
135. Wojtovich AP, Urciuoli WR, Chatterjee S, Fisher AB, Nehrke K, Brookes PS. Kir6.2 is not the mitochondrial KATP channel but is required for cardioprotection by ischemic preconditioning. Am J Physiol Heart Circ Physiol, 2013; 304: H1439-45.
136. Nakaya H. Role of ATP-Sensitive K+ Channels in Cardiac Arrhythmias. J Cardiovasc Pharmacol Ther, 2013.
137. Seharaseyon J, Sasaki N, Ohler A, Sato T, Fraser H, Johns DC, O'Rourke B, Marban E. Evidence against functional heteromultimerization of the KATP channel subunits Kir6.1 and Kir6.2. J Biol Chem, 2000; 275: 17561-5.
138. Foster DB, Ho AS, Rucker J, Garlid AO, Chen L, Sidor A, Garlid KD, O'Rourke B. Mitochondrial ROMK channel is a molecular component of mitoK(ATP). Circ Res, 2012; 111: 446-54.
139. Ye B, Kroboth SL, Pu JL, Sims JJ, Aggarwal NT, McNally EM, Makielski JC, Shi NQ. Molecular identification and functional characterization of a mitochondrial sulfonylurea receptor 2 splice variant generated by intraexonic splicing. Circ Res, 2009; 105: 1083-93.
140. Rines AK, Bayeva M, Ardehali H. A new pROM king for the mitoK(ATP) dance: ROMK takes the lead. Circ Res, 2012; 111: 392-3.
141. Sasaki N, Sato T, Marban E, O'Rourke B. ATP consumption by uncoupled mitochondria activates sarcolemmal K(ATP) channels in cardiac myocytes. Am J Physiol Heart Circ Physiol, 2001; 280: H1882-8.
142. Ryu SY, Lee SH, Ho WK. Generation of metabolic oscillations by mitoKATP and ATP synthase during simulated ischemia in ventricular myocytes. J Mol Cell Cardiol, 2005; 39: 874-81.
143. Aon MA. From isolated to networked: a paradigmatic shift in mitochondrial physiology. Front Physiol, 2010; 1: 20.
144. Akar FG, O'Rourke B. Mitochondria are sources of metabolic sink and arrhythmias. Pharmacol Ther, 2011; 131: 287-94.
145. Aon MA, Cortassa S, Akar FG, Brown DA, Zhou L, O'Rourke B. From mitochondrial dynamics to arrhythmias. Int J Biochem Cell Biol, 2009; 41: 1940-8.
146. Aon MA, Cortassa S, Marban E, O'Rourke B. Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes. J Biol Chem, 2003; 278: 44735-44.
147. Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med, 2000; 192: 1001-14.
148. Akar FG, Aon MA, Tomaselli GF, O'Rourke B. The mitochondrial origin of postischemic arrhythmias. J Clin Invest, 2005; 115: 3527-35.
149. Zhou L, Solhjoo S, Millare B, Plank G, Abraham MR, Cortassa S, Trayanova N, O'Rourke B. Effects of Regional Mitochondrial Depolarization on Electrical Propagation: Implications for Arrhythmogenesis. Circ Arrhythm Electrophysiol, 2014.
150. Storey NM, Stratton RC, Rainbow RD, Standen NB, Lodwick D. Kir6.2 limits Ca(2+) overload and mitochondrial oscillations of ventricular myocytes in response to metabolic stress. Am J Physiol Heart Circ Physiol, 2013; 305: H1508-18.
151. Smith RM, Visweswaran R, Talkachova I, Wothe JK, Tolkacheva EG. Uncoupling the mitochondria facilitates alternans formation in the isolated rabbit heart. Am J Physiol Heart Circ Physiol, 2013; 305: H9-18.
152. Szewczyk A, Kajma A, Malinska D, Wrzosek A, Bednarczyk P, Zablocka B, Dolowy K. Pharmacology of mitochondrial potassium channels: dark side of the field. FEBS Lett, 2010; 584: 2063-9.
153. Coetzee WA. Multiplicity of effectors of the cardioprotective agent, diazoxide. Pharmacol Ther, 2013; 140: 167-75.
154. Das B, Sarkar C. Mitochondrial K ATP channel activation is important in the antiarrhythmic and cardioprotective effects of nonhypotensive doses of nicorandil and cromakalim during ischemia/reperfusion: a study in an intact anesthetized rabbit model. Pharmacol Res, 2003; 47: 447-61.
155. Das B, Sarkar C. Is the sarcolemmal or mitochondrial K(ATP) channel activation important in the antiarrhythmic and cardioprotective effects during acute ischemia/reperfusion in the intact anesthetized rabbit model? Life Sci, 2005; 77: 1226-48.
156. Matejikova J, Ravingerova T, Pancza D, Carnicka S, Kolar F. Mitochondrial KATP opening confers protection against lethal myocardial injury and ischaemia-induced arrhythmias in the rat heart via PI3K/Akt-dependent and-independent mechanisms. Can J Physiol Pharmacol, 2009; 87: 1055-62.
157. Kolar F, Neckar J, Ostadal B. MCC-134, a blocker of mitochondrial and opener of sarcolemmal ATP-sensitive K+ channels, abrogates cardioprotective effects of chronic hypoxia. Physiol Res, 2005; 54: 467-71.
158. Quindry JC, Schreiber L, Hosick P, Wrieden J, Irwin JM, Hoyt E. Mitochondrial KATP channel inhibition blunts arrhythmia protection in ischemic exercised hearts. Am J Physiol Heart Circ Physiol, 2010; 299: H175-83.
159. Gonca E, Bozdogan O. Both mitochondrial KATP channel opening and sarcolemmal KATP channel blockage confer protection against ischemia/reperfusion-induced arrhythmia in anesthetized male rats. J Cardiovasc Pharmacol Ther, 2010; 15: 403-11.
160. Bozdogan O, Kaya ST, Yasar S, Orallar H. Effect of ATPdependent channel modulators on ischemia-induced arrhythmia change depending on age and gender. Exp Biol Med (Maywood), 2013; 238: 1170-9.
161. Ranki HJ, Crawford RM, Budas GR, Jovanovic A. Ageing is associated with a decrease in the number of sarcolemmal ATPsensitive K+ channels in a gender-dependent manner. Mech Ageing Dev, 2002; 123: 695-705.
162. Sato T, Costa AD, Saito T, Ogura T, Ishida H, Garlid KD, Nakaya H. Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther, 2006; 316: 182-8.
163. Puglisi JL, Bers DM. LabHEART: an interactive computer model of rabbit ventricular myocyte ion channels and Ca transport. Am J Physiol Cell Physiol, 2001; 281: C2049-60.
164. Roberts BN, Yang PC, Behrens SB, Moreno JD, Clancy CE. Computational approaches to understand cardiac electrophysiology and arrhythmias. Am J Physiol Heart Circ Physiol, 2012; 303: H766-83.
165. Ferrero JM, Jr., Saiz J, Ferrero JM, Thakor NV. Simulation of action potentials from metabolically impaired cardiac myocytes. Role of ATP-sensitive K+ current. Circ Res, 1996; 79: 208-21.
166. Shaw RM, Rudy Y. Electrophysiologic effects of acute myocardial ischemia: a theoretical study of altered cell excitability and action potential duration. Cardiovasc Res, 1997; 35: 256-72.
167. Rodriguez B, Ferrero JM, Jr., Trenor B. Mechanistic investigation of extracellular K+ accumulation during acute myocardial ischemia: a simulation study. Am J Physiol Heart Circ Physiol, 2002; 283: H490-500.
168. Michailova A, Lorentz W, McCulloch A. Modeling transmural heterogeneity of K(ATP) current in rabbit ventricular myocytes. Am J Physiol Cell Physiol, 2007; 293: C542-57.
169. Trenor B, Ferrero JM, Jr., Rodriguez B, Montilla F. Effects of pinacidil on reentrant arrhythmias generated during acute regional ischemia: a simulation study. Ann Biomed Eng, 2005; 33: 897-906.
170. Olson TM, Terzic A. Human K(ATP) channelopathies: diseases of metabolic homeostasis. Pflugers Arch, 2010; 460: 295-306.
171. Nichols CG, Singh GK, Grange DK. KATP channels and cardiovascular disease: suddenly a syndrome. Circ Res, 2013; 112: 1059-72.